
|Articles|July 1, 2001
- Pharmaceutical Executive-07-01-2001
- Volume 0
- Issue 0
Submerged
Author(s)Wayne Koberstein
Is the pharmaceutical industry surrounded by its critics? Can the industry be liberated from the moral bind others want to impose on it? Those are questions I asked and attempted to answer in two recent editorials (PE April and June 2001). Actually, the simple answer was yes to both. But other answers prove more complex.
Advertisement
Articles in this issue
over 24 years ago
Pharmacies: OTC Price Warsover 24 years ago
One Disease at a Timeover 24 years ago
Overview of the Industry: A World of Opportunitiesover 24 years ago
The Power Shiftover 24 years ago
A Giant Stumblesover 24 years ago
Overruled: No More Dual Pricingover 24 years ago
Generic ThreatNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Brent Saunders: Eyeing New Horizons
2
TrumpRX Has a Blind Spot and It Can Redefine Patient Access
3
Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial
4
The Cost of Fixing Pharma
5





